QYOU Media India Completes Sale of "Q" Broadcast Channel in India
QYOU Media Accelerates its Strategic Shift towards a Creator Economy and Social Media Marketing-Focused Business Model
MUMBAI, India and TORONTO , May 28, 2025 /CNW/ - QYOU Media Inc., (TSXV: QYOU) (OTCQB: QYOUF), via its subsidiary corporation, QYOU Media India Pvt. Ltd., has announced the completion of the sale of its India free-to-air broadcast channel, "Q TV", to Oscar Media Pvt. Ltd. Oscar Media operates multiple channels across India in a variety of local languages. Terms of the transaction were not disclosed.
The sale of the broadcast channel asset marks another step forward by QYOU Media, Inc., to execute on its previously announced go forward strategy focusing its resources and strategic efforts on high-growth segments within the global digital creator economy and social media marketing. These efforts will be carried out via the current business units in both North America and India , with the goal for future expansion. The company also continues to move ahead on the process to publicly list Chatterbox Technologies (Chtrbox), its India based influencer marketing and creator economy driven business, on the BSE (formerly known as the Bombay Stock Exchange). This will create the first publicly listed social media and influencer marketing business in India and will be led by Raj Mishra, former Country Manager of TikTok India.
QYOU Media CEO and Co-Founder Curt Marvis commented, "Parting ways with the television business that helped launch us in India is bittersweet, but this transition empowers us to concentrate fully on the future—driven by the explosive growth in social media , AI and Creator-led marketing. We believe this pivot will unlock greater long-term value for our shareholders. The television business has been marked by huge upheaval globally and it was simply time for us to move decisively into the areas of our business where we see the strongest positive growth opportunities for many years to come. We wish Oscar Media the best of luck with the channel and we thank all the people who helped build it with us along the way."
About QYOU Media
Among the fastest growing creator driven media companies, QYOU Media operates in India and the United States through its subsidiaries, producing, distributing and monetizing content created by social media influencers and digital content stars. Our influencer marketing business in India , Chtrbox, is an influencer and marketing platform and agency, connecting brands/products and social media influencers. In the United States , we power major film studios, game publishers and brands to create content and market via creators and influencers. Founded and managed by industry veterans from Lionsgate, MTV, Disney, Sony and TikTok. QYOU Media's millennial and Gen Z-focused content has reached more than one billion consumers. Experience our work at www.qyoumedia.com and https://www.chtrbox.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
5 hours ago
- National Post
Cricket superstar Virat Kohli and Royal Challengers finally end 18-year IPL title drought
Fireworks went off around India as Royal Challengers Bengaluru ended its drought by finally being crowned Indian Premier League's champion. Article content In cricket's largest stadium — the Narendra Modi Stadium in Ahmedabad — that packed in 132,000 fans, Bengaluru held Punjab Kings to 184 for seven after posting 190 for nine in an exciting finale. Article content Article content At the 18th attempt, the Royal Challengers finally struck gold after falling at the final hurdle in 2009, 2011 and 2016, and one of the game's greatest players finally got his hands on the one trophy that eluded him all these years. Article content Virat Kohli was thrown in the air by his excited teammates after a slight scare thrown into them by Punjab's Shashank Singh, who blasted 61 off 30 balls with a 6, 4, 6 and 6. Article content But it was a little too late to stop Kohli and his teammates from getting their hands on the most-prized cricket club trophy in the world. Article content As one would expect in cricket-crazed India, the country came to a virtual standstill for roughly four hours and, according to reports, the hysteria in Bengaluru hit an all-time high with rickshaw drivers offering free rides anywhere the game was televised. Article content At one time it appeared the undisputed poster boy of the IPL and Indian cricket was destined to follow in the footsteps of greats such as soccer's Johan Cruyff, George Best and Paolo Maldini of falling short of the ultimate silverware. But it was not to be. Article content But the right-handed superstar and the face of Indian cricket after the great Sachin Tendulkar retired won the ODI World Cup at 22 and, two years later at 24, he was a member of India's Champions Trophy. In the past 12 months the 36-year-old Kohli completed the World Twenty20 Cup and the Champions Trophy double. Article content Article content Kohli did his job in the final with a top score of 43 from 35 balls, but with just three boundaries, and skipper Rajat Patidar weighed in with 26 off 16. Article content Article content Another player who played a huge part in the victory was spinner Krunal Pandya, who grabbed two for 17 with 12 dot balls and conceded just one boundary. Article content For Punjab, Arshdeep Singh and Kyle Jamieson took three wickets apiece, with Arshdeep striking three times in the final over to derail RCB's hopes of posting more than 200. Article content 'This win is as much for the fans as it is for the team,' Kohli said after the game. 'It's been 18 long years. I've given this team my youth, my prime and my experience. I've tried to win this every season when I come, give it everything I have. To have this moment is an unbelievable feeling. Article content 'I never thought this day would come. I was overcome with emotion as soon as the last ball was bowled. This means so much to me. I've given each and every ounce of my energy to this team. To have finally won the IPL is an amazing feeling. I am so very grateful for this victory, so thankful for God for giving me finally tonight. I just put my head down, stay humble, work as hard as I possibly, find ways to help the team,' Kohli added.
Globe and Mail
8 hours ago
- Globe and Mail
Digital Silk Identifies Surge in Influencer-Led Digital Marketing Campaigns Among U.S. DTC Brands
Los Angeles, California--(Newsfile Corp. - June 3, 2025) - Digital Silk, an award-winning agency specializing in brand strategies, custom websites and digital marketing campaigns, is announcing increased client demand among U.S. direct-to-consumer (DTC) brands for influencer-led digital marketing strategies in 2025. According to new data from eMarketer, U.S. influencer marketing spend may potentially exceed $10 billion in 2025. This rise is linked to a growing preference for performance-focused influencer partnerships, micro-creator collaborations, and shoppable short-form video content. As DTC brands seek to optimize marketing budgets, many are reallocating spend toward influencer strategies that aim to deliver targeted reach and measurable customer engagement. To view an enhanced version of this graphic, please visit: Influencer Campaign Trends for DTC Brands Digital Silk has observed a shift among emerging DTC brands toward leveraging niche creator partnerships and integrating trackable special offer codes to monitor sales performance. Recent research highlights that short-form videos can drive up to 2.5 times more engagement compared to static posts, while micro- and nano-creators are increasingly favoured for niche audience targeting. Core Elements of Influencer Campaigns Micro-Creator Collaborations: Niche influencers can potentially bring higher engagement rates and build trust within specialized audiences. UGC Whitelisting: Brands amplify paid media by running ads through creator accounts, with the aim of lowering cost per thousand impressions (CPM). Shoppable Short-Form Video: Interactive links streamline the path from content view to checkout Attribution Tracking: Unique special offer codes and affiliate links provide clear sales data. "Influencer campaigns are evolving into measurable, performance-driven marketing tools," says Gabriel Shaoolian, CEO of Digital Silk. "For DTC brands, they offer opportunities to connect with audiences in authentic and trackable ways." U.S. influencer marketing spend may potentially surpass $10 billion in 2025. Brands increasingly leveraging micro- and nano-creators for targeted audience reach. Short-form videos achieving up to 2.5x higher engagement compared to static posts. Looking Ahead As influencer marketing continues to evolve, DTC brands are expected to deepen focus on scalable, data-driven campaigns that blend authenticity with measurable results. Digital Silk remains committed to helping brands navigate this dynamic landscape by providing strategic digital marketing services tailored to the unique demands of the influencer economy. About Digital Silk Digital Silk is a full-service Digital Marketing Agency focused on growing brands online. With a team of seasoned experts, Digital Silk delivers industry-leading digital experiences through strategic branding and cutting-edge web design with the aim to drive more conversions and digital marketing services to boost awareness and engagement.
National Post
14 hours ago
- National Post
Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US
Article content LEXINGTON, Mass. — Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE), including its subsidiaries/affiliates, hereafter referred to as 'Zydus,' designed to accelerate clinical development, scale global manufacturing, and expand patient access to botensilimab and balstilimab (BOT/BAL). Article content The strategic collaboration includes an exchange of Agenus' state-of-the-art biologics CMC facilities in Emeryville, CA and Berkeley, CA for upfront consideration of $75M; Agenus to receive up to an additional $50M in contingent payments triggered by BOT/BAL production orders. Zydus, an India-based multinational pharmaceutical company with over 27,000 employees and operations in 55 countries, will launch a BioCDMO business using the facilities as their flagship U.S. sites to provide biologics contract manufacturing services to biopharmaceutical companies globally. Agenus will become Zydus' first BioCDMO customer through an exclusive manufacturing agreement for BOT/BAL to ensure the combination regimen's BLA and launch readiness needs. This collaboration enables Agenus to unlock the value of its manufacturing assets and secure strategic capital to drive BOT/BAL toward global regulatory engagement and commercialization. Article content Agenus will also grant Zydus an exclusive license to develop and commercialize BOT and BAL in India and Sri Lanka, capitalizing on Zydus' established local market presence and infrastructure. Zydus will pay Agenus a 5 percent royalty on net sales in those countries. Article content In a demonstration of mutual commitment, Zydus will also make a strategic equity investment in Agenus by purchasing approximately 2.1 million shares of common stock at $7.50 per share, totaling approximately $16 million in gross proceeds. Agenus intends to apply the net proceeds from the sale of the purchased shares for working capital and general corporate purposes, and will accelerate ongoing clinical development, registration and potential commercialization of BOT/BAL. Article content By uniting Agenus' pioneering research and development capabilities with Zydus' worldwide manufacturing, commercialization and operational strength, this partnership sets the stage for a new era in cancer immunotherapy in India and beyond. Article content 'With a trade agreement between the United States and India seemingly imminent, there is a renewed sense of confidence by trading partners in both countries in the future of Indian-American relations,' said Dr. Garo Armen, CEO of Agenus. 'There is also a growing recognition by both countries of the need for the United States to ensure that biopharma supply chains are secure. We are working with Zydus to accelerate future clinical trials for BOT/BAL and eventually its global footprint in oncology therapeutics. This agreement is an expression of confidence in the future of Agenus and in the regulatory environment of the United States. The administration has created an environment that has brought these two trading partners together. The United States is the second largest trading partner with India. For these reasons and the strong collaborative spirit we feel with our new partners at Zydus, we decided to enter into this partnership now.' Article content 'We are thrilled to be partnering with Agenus to advance BOT/BAL, which has the potential to benefit thousands of patients in our core markets of India and Sri Lanka annually and millions of solid tumor patients globally. We plan to run clinical trials testing BOT/BAL in both early-stage and late-stage disease, along with expansion beyond colorectal cancer to other major disease settings like triple negative breast cancer,' said Dr. Sharvil Patel, Managing Director at Zydus Lifesciences Ltd. Article content The transaction is subject to customary closing conditions and satisfactory due diligence. The parties aim to complete closing agreements within 60 days. Article content Conference Call and Webcast Article content As part of this effort, Agenus was advised by Biotech Value Advisors (BVA), a strategic advisory firm, which provided guidance on transaction structure, partner selection and negotiations. Article content About Agenus Article content Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels. Article content About Zydus Lifesciences Article content Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27,000 people worldwide, including 1,400 scientists engaged in R&D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. For more details visit Article content Botensilimab (BOT) is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to 'cold' tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses. Article content Approximately 1,200 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus' investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit Article content About Balstilimab (BAL) Article content Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in >900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types. Article content Forward-Looking Statements Article content This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words 'may,' 'believes,' 'expects,' 'anticipates,' 'hopes,' 'intends,' 'plans,' 'forecasts,' 'estimates,' 'will,' 'establish,' 'potential,' 'superiority,' 'best in class,' and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2024, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Article content Article content Article content Article content Article content Contacts Article content Article content Article content
